Orthocell Ltd. engages in the business of developing and commercializing biological medical devices and cell therapies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is a sterile, resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen scaffold used in peripheral nerve repair. OrthoACI or autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The firm is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Follow-Up Questions
Quelle est la performance du prix de l'action ORHHF ?
Le prix actuel de ORHHF est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Orthocell Ltd ?
Orthocell Ltd appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Orthocell Ltd ?
La capitalisation boursière actuelle de Orthocell Ltd est de $0
Est-ce que Orthocell Ltd est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Orthocell Ltd, y compris 1 achat fort, 3 achat, 1 maintien, 0 vente et 1 vente forte
